Market Access | Getting therapies in patients' hands

News

Eisai debuts biliary tract cancer drug in Japan

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug

Market Access

EMA’s strategy for speeding up drug approvals in the EU

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Trump picks celebrity doc Mehmet Oz to lead Medicare

Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid Services

News

Dr Sam Roberts, NICE chief executive, said AstraZeneca and Daiichi Sankyo had not offered a fair price

NICE blames companies for breakdown in Enhertu talks

Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Trump picks celebrity doc Mehmet Oz to lead Medicare

Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid Services

News

NICE blames companies for breakdown in Enhertu talks

Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.

News

Eisai debuts biliary tract cancer drug in Japan

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

Press Releases

News

2019-Gene-Therapy-Muscular-Dystrophy_ProgFeature_IMG

Solid Biosciences acquires AavantiBio, conducts $75 million ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a

News

AstraZeneca pays record 660% premium for gene editing compan...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately

Views & Analysis

Market Access

EMA’s strategy for speeding up drug approvals in the EU

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike

Market Access

Looking to history to prepare for America’s uncertain future

In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration

Deep Dive

Market Access

Heard on the pipeline: Access to medications

Solving the challenge of access to medication has fuelled many a debate among healthcare stakeholders over the years.

Market Access

Integrating market access considerations into biopharmaceuti...

The biopharmaceutical industry operates at the intersection of health innovation and market viability, where the significance of integrating market access insights into investment decisions

Market Access

Mind the gap: What is causing the ongoing ADHD drug shortage...

Since late 2022, medications for Attention Deficit/Hyperactivity Disorder, or ADHD, have been in a shortage in the United States and the UK.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Looking to history to prepare for America’s uncertain future

In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration

Market Access

Man listening to Podcast with Alice Valder Curran about Medicare drug pricing negotiations

Medicare drug pricing negotiations: What comes next?

Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the

Market Access

Approaching the regulatory world with passion: CERs and EU M...

There has been significant evolution in the European regulatory landscape over the past 10 years, particularly in terms of requirements for clinical evaluation, driven in part by

Video

Market Access

Health Innovators – Aleks Engel

One month ago, editor-in-chief Jonah Comstock travelled to Copenhagen, Denmark to visit the Novo Nordisk Foundation.

Market Access

Health Innovators – Søren Møller

Søren Møller, managing partner for seed investments at Novo Holdings, believes successful start-ups in healthcare share a trifecta of component pieces: “great science, the right talent, and

Market Access

Health Innovators – Thomas Carlsen

Back in September, the Novo Nordisk Foundation announced th

White Papers

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Computer Gaming: The Future of Decision-Making for Life Scie...

How can life science brands identify winning strategic decisions when there are so many variables to consider?

Event

Market Access

Reuters Pharma Europe 2024

From the 16th to the 18th of April, industry leaders will gather in one of Spain’s most iconic cities as Reuters Pharma Europe returns for 2024.

Market Access

Reuters Pharma USA 2024 - Day 2

Wednesday brings much more Cell and Gene Therapy content, but we’ll also dip into the Marketing and Commercial tracks, looking at real-world evidence, value-based care, and omnichannel mark

Market Access

Live coverage: Reuters Pharma USA 2024

At Reuters Pharma USA, a who’s who of executives from major pharma companies will gather in Philadelphia to go in-depth on every part of the business, from marketing and market access to re

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Market Access

Six of the ten leading policy strategists from Avalere

Partner Content

Policy strategists to cite the seismic policy changes for 20...

Ten leading policy strategists from Avalere, part of Avalere Health, will share their insights on the significant policy changes that will shape 2024

Events

Partner Content

SMi’s 5th Annual 3D Cell Culture Virtual Conference

3D Cell Culture

Partner Content

Partner Content

Patient and market insights from leading KOLs and life scien...

Insights from leading KOLs in new Dermatology eBook

Eisai debuts biliary tract cancer drug in Japan

EMA’s strategy for speeding up drug approvals in the EU

Pfizer bags EU okay for haemophilia drug Hympavzi

Trump picks celebrity doc Mehmet Oz to lead Medicare

NICE blames companies for breakdown in Enhertu talks

Pfizer bags EU okay for haemophilia drug Hympavzi

Trump picks celebrity doc Mehmet Oz to lead Medicare

NICE blames companies for breakdown in Enhertu talks

Eisai debuts biliary tract cancer drug in Japan

Pfizer bags EU okay for haemophilia drug Hympavzi

Solid Biosciences acquires AavantiBio, conducts $75 million ...

AstraZeneca pays record 660% premium for gene editing compan...

EMA’s strategy for speeding up drug approvals in the EU

Looking to history to prepare for America’s uncertain future

Heard on the pipeline: Access to medications

Integrating market access considerations into biopharmaceuti...

Mind the gap: What is causing the ongoing ADHD drug shortage...

Innovative Medicines Fund and the opportunity for ICSs to mo...

Medical Informatics and Rare Disease: a bridge between two w...

ICSs - an opportunity to improve Patient & Market Access at ...

Looking to history to prepare for America’s uncertain future

Medicare drug pricing negotiations: What comes next?

Approaching the regulatory world with passion: CERs and EU M...

Health Innovators – Aleks Engel

Health Innovators – Søren Møller

Health Innovators – Thomas Carlsen

Navigating Routes to Commercial Excellence in Cell and Gene ...

Computer Gaming: The Future of Decision-Making for Life Scie...

Reuters Pharma Europe 2024

Reuters Pharma USA 2024 - Day 2

Live coverage: Reuters Pharma USA 2024

Innovative contracting in Europe – a Trojan horse?

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

Policy strategists to cite the seismic policy changes for 20...

SMi’s 5th Annual 3D Cell Culture Virtual Conference

Patient and market insights from leading KOLs and life scien...

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Sustainability
--Clinical
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Frontiers Health 2023
-Frontiers Health 2024
-Future of Generics
-Understanding HCPs
-World Without Disease Summit
-The Future of Generics

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Sustainability
--Clinical
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Frontiers Health 2023
-Frontiers Health 2024
-Future of Generics
-Understanding HCPs
-World Without Disease Summit
-The Future of Generics

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks